Aliskiren combined with other inhibitors of the renin–angiotensin system increases the risk of hyperkalemia. This risk does not translate into an increased incidence of acute kidney injury, suggest the results of a meta-analysis. However, further research is needed to fully evaluate the safety of combination therapy with aliskiren.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
US Food and Drug Administration. FDA approves new drug treatment for high blood pressure [online], (2007).
Harel, Z. et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ 344, e42 (2012).
Gormley, K., Dong, Y. & Sagnella, G. A. Regulation of the epithelial sodium channel by accessory proteins. Biochem. J. 371, 1–14 (2003).
Toto, R. D., Mitchell, H. C., Lee, H. C., Milam, C. & Pettinger, W. A. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann. Intern. Med. 115, 513–519 (1991).
Mann, J. F. et al. for the TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. Effect of telmisartan on renal outcomes: a randomized trial. Ann. Intern. Med. 151, 1–10 (2009).
Ting, R. Z., Luk, A. O. & Chan, J. C. Treatment and landmark clinical trials for renoprotection. Contrib. Nephrol. 170, 184–195 (2011).
Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L. & Toto, R. D. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 20, 2641–2650 (2009).
Juurlink, D. N. et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 351, 543–551 (2004).
Oparil, S. et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370, 221–229 (2007).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
R. D. Toto is a consultant for and has received research funding from Novartis.
Rights and permissions
About this article
Cite this article
Toto, R. RAS blockade, hyperkalemia and AKI—look and you will find. Nat Rev Nephrol 8, 257–258 (2012). https://doi.org/10.1038/nrneph.2012.62
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2012.62
